EGFR and acute lymphoblastic leukemia: Further, unlike previous phase III studies and meta‐analyses of EGFR‐TKI treatment, the PFS in the ALL group was equivalent between 19 del and L858R subgroups, which might have affected the result for the AI fit and unfit groups.